Preclinical Study of Locoregional Therapy of Hepatocellular Carcinoma by Bioelectric Ablation with Microsecond Pulsed Electric Fields (μsPEFs).
Unresectable hepatocellular carcinoma (HCC) needs locoregional ablation as a curative or downstage therapy. Microsecond Pulsed Electric Fields (μsPEFs) is an option. A xenograft tumor model was set up on 48 nude mice by injecting human hepatocellular carcinoma Hep3B cells subcutaneously. The tumor-bearing mice were randomly divided into 3 groups: μsPEFs treated, sham and control group. μsPEFs group was treated by μsPEFs twice in 5 days. Tumor volume, survival, pathology, mitochondria function and cytokines were followed up. μsPEFs was also conducted on 3 swine to determine impact on organ functions. The tumors treated by μsPEFs were completely eradicated while tumors in control and sham groups grew up to 2 cm(3) in 3 weeks. The μsPEFs-treated group indicated mitochondrial damage and tumor necrosis as shown in JC-1 test, flow cytometry, H&E staining and TEM. μsPEFs activates CD56+ and CD68+ cells and inhibits tumor proliferating cell nuclear antigen. μsPEFs inhibits HCC growth in the nude mice by causing mitochondria damage, tumor necrosis and non-specific inflammation. μsPEFs treats porcine livers without damaging vital organs. μsPEFs is a feasible minimally invasive locoregional ablation option.
1] The Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China [2] Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang, 310003, China.
Xinhua
X
Chen
1] The Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China [2] Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang, 310003, China.
Zhigang
Z
Ren
The State Key Laboratory of Power Transmission Equipment &System Security and New Technology, Chongqing University, Chongqing, 400030, China.
Chengxiang
C
Li
The State Key Laboratory of Power Transmission Equipment &System Security and New Technology, Chongqing University, Chongqing, 400030, China.
Fei
F
Guo
The State Key Laboratory of Power Transmission Equipment &System Security and New Technology, Chongqing University, Chongqing, 400030, China.
Dianbo
D
Zhou
1] The Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China [2] Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang, 310003, China.
Jianwen
J
Jiang
The Department of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250014, China.
Xinmei
X
Chen
The Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Jihong
J
Sun
The State Key Laboratory of Power Transmission Equipment &System Security and New Technology, Chongqing University, Chongqing, 400030, China.
Chenguo
C
Yao
1] The Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China [2] Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang, 310003, China.
Shusen
S
Zheng
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods; D045744:Cell Line, Tumor; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism / Q000628:therapy*; D008114:Liver Neoplasms, Experimental / Q000378:metabolism / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D008928:Mitochondria / Q000378:metabolism; D009336:Necrosis / Q000378:metabolism; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D047368:Tumor Burden / Q000502:physiology; D023041:Xenograft Model Antitumor Assays / Q000379:methods
D018809:Proliferating Cell Nuclear Antigen